ClinicalTrials.gg
RecruitingNCT03870620Updated Apr 10, 2025

Metastatic Breast Cancer in Austria

An observational study in Breast Cancer, Breast Carcinoma and Breast Tumor, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Recruiting at 16 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2015; still recruiting 11 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Breast Neoplasms with a site in Austria — 24 open to participants now, 62 under way, 36 of them phase 3. Breast Neoplasms · Austria.

Planned enrollment
3rd of 34
5,000 · median 1,135
Started
2015
with 13 others
Observational
34 of 230
8 open now
Primary completion
2025-06
later than 13 of 61 live
Registered
158th of 230
by date
Lead sponsor
6 of 230
Arbeitsgemeinschaft medikamentoese Tumortherapie

Among the 230 studies in Breast Neoplasms with a site in Austria, this one is the 3rd largest by planned enrollment of the 34 observational ones that give a count, is one of 14 that started in 2015, is one of 34 observational ones, reaches primary completion later than 13 of the 61 other live ones, and was the 158th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

24 of the 230 studies in Breast Neoplasms with a site in Austria are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Breast Neoplasms with a site in Austria, or all of them as a file.
02

Study summary

Breast cancer is the most common cancer among women worldwide. In Austria, this diagnosis is made more than 5000 times a year (STATISTICS AUSTRIA, Austrian Cancer Registry, as of 24.09.2012). Of these, already 5% to 10% have distant metastases at the time of initial diagnosis, and up to 30% of the node-negative tumours and up to 70% of the node-positive tumours metastasise at a later date. Metastatic breast cancer has not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardised documentation of this disease. The aim of the registry is to answer both epidemiological and therapy-specific questions.

This registry is a prospective and retrospective, multicentre collection of data on patients with metastatic breast cancer in Austria. All tumour characteristics, medical histories and also treatment sequences are documented in anonymised form.

Read the detailed description

The present AGMT registry will provide accurate documentation of initial disease progression and initial tumour characteristics in patients with metastatic breast cancer in Austria. The data collected will include: median age at metastasis, median disease-free survival (DFS) between initial diagnosis or first date of absence of disease and occurrence of metastasis, histological subtype of the primary tumour, initial TNM stage, grade and receptor status of the primary tumour, type and form of adjuvant therapy, pattern of metastasis and metastasis site. Characteristics that have a negative prognostic value are expected to be overrepresented in the metastatic patient group.

Also, this AGMT registry is intended to assess the distribution pattern of these metastatic stage subtypes in Austria. Additionally, their influence on treatment strategy and outcome is to be studied. Furthermore, the frequency and tumour characteristics of breast cancer in male patients will be assessed and the influence of gender on treatment strategies identified.

The AGMT breast cancer registry will conduct an exact analysis of survival data, thereby enabling accurate calculations of average survival duration in patients with metastatic breast cancer in Austria. Further parameters that reflect the quality or course of oncological treatment are the survival rates from the time of metastasis development at 1, 2 and 5 years after diagnosis.

This AGMT registry is intended to investigate the response to various therapies in a real life population in relation to previous treatments, concomitant diseases and breast cancer subtype. The aim is to assess which therapies are used at which time point and on which disease subtype they depend.

03

Conditions studied

  • Breast Cancer
  • Breast Carcinoma
  • Breast Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This registry is a prospective and retrospective, multicentre collection of data on patients with metastatic breast cancer in Austria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological evidence of breast cancer
  • Histological and/or radiological evidence of
  • Metastasis within 10 years of registry initiation
  • Signed (if a patient has already died at the time of entry, the entry can be made without a declaration of consent)

Exclusion criteria

Exclusion Criteria:

  • Due to the non-interventional design of the registry there are no specific exclusion criteria.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
5,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Number of patients with prognostic factors for metastatic breast cancer

    Time frame: 10 years

  2. Number of patients according to molecular subtypes

    Time frame: 10 years

  3. Frequency and tumour characteristics of breast cancer in male patients

    Time frame: 10 years

  4. Overall survival of patients with metastatic breast cancer in Austria

    Time frame: 10 years

07

Study locations

16 of 16 sites recruiting
  • Kepler Universitätsklinikum; Univ.-Klinik für Hämatologie und Internistische Onkologie
    Linz, Oberösterreich 4020, Austria
    Recruiting
    • Clemens Schmitt, MD · Principal investigator
  • Ordensklinikum Linz GmbH - Barmherzige Schwestern; Interne I: Medizinische Onkologie und Hämatologie
    Linz, Oberösterreich 4020, Austria
    Recruiting
    • Renate Pusch, MD · Principal investigator
  • Pyhrn-Eisenwurzen Klinikum Steyr; Innere Medizin II: Onkologie, Gastroenterologie, Angiologie
    Steyr, Oberösterreich 4400, Austria
    Recruiting
    • Johannes Andel, MD · Principal investigator
  • Klinikum Wels-Grieskirchen GmbH; Abteilung für Innere Medizin IV
    Wels, Oberösterreich 4600, Austria
    Recruiting
    • Sonja Heibl, MD · Principal investigator
  • Steiermärkische Krankenanstalten- gesellschaft m. b. H. LKH-Univ. Klinikum Graz; Universitätsklinik für Innere Medizin; Klinische Abteilung für Onkologie
    Graz, Steiermark 8036, Austria
    Recruiting
    • Gabriel Rinnerthaler, MD · Principal investigator
  • Landeskrankenhaus - Universitätskliniken Innsbruck; Universitätsklinik für Frauenheilkunde Innsbruck
    Innsbruck, Tirol 6020, Austria
    Recruiting
    • Daniel Egle, MD · Principal investigator
  • BKH Kufstein; Innere Medizin: Interne II und onk. Tagesklinik
    Kufstein, Tirol 6330, Austria
    Recruiting
    • August Zabernigg, MD · Principal investigator
  • LKH Feldkirch; Innere Medizin II/ Interne E (Hämatologie und Onkologie)
    Feldkirch, Vorarlberg 6800, Austria
    Recruiting
    • Bernd Hartmann, MD · Principal investigator
  • Krankenhaus St. Josef Braunau; Inneren Medizin 2
    Braunau am Inn, 5280, Austria
    Recruiting
    • Florian Roitner, MD · Principal investigator
  • Krankenhaus der Stadt Dornbirn; Brustgesundheitszentrum Dornbirn
    Dornbirn, 6850, Austria
    Recruiting
    • Christopher Hager, MD · Principal investigator
  • Steiermärkische Krankenanstalten- gesellschaft m.b.H. LKH Hochsteiermark; Department für Hämato-Onkologie
    Leoben, 8700, Austria
    Recruiting
    • Angelika Pichler, MD · Principal investigator
  • Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität; Universitätsklinik für Innere Medizin III Salzburg
    Salzburg, 5020, Austria
    Recruiting
    • Simon Gampenrieder, MD · Principal investigator
  • Universitätsklinikum St. Pölten; Abteilung für Innere Medizin 1
    St. Pölten, 3100, Austria
    Recruiting
    • Petra Pichler-Izmir, MD · Principal investigator
  • Klinik Ottakring; 1. Med. Abteilung, Zentrum f. Onkologie, Hämatologie und Palliativmedizin
    Vienna, 1160, Austria
    Recruiting
    • Kathrin Strasser-Weippl, MD · Principal investigator
  • AKH Wien; Universitätsklinik für Frauenheilkunde: Klin. Abt. f. Allg. Gynäkologie und gynäkologische Onkologie
    Wien, 1090, Austria
    Recruiting
    • Christian Singer, MD · Principal investigator
  • UK AKH Wien: Universitätsklinik für Innere Medizin I: Klinische Abteilung für Onkologie
    Wien, 1090, Austria
    Recruiting
    • Rupert Bartsch, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2015 (actual). Primary completion is estimated for Jun 2025, 120 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 120 months is above that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2019
First posted
Mar 12, 2019
StartActual
Jun 15, 2015
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2025
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03870620
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Responsible party
Sponsor
First posted
Mar 12, 2019
Start date
Jun 15, 2015
Primary completion
Jun 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Apr 10, 2025

Study contacts

Daniela Wolkersdorfer
Contact
d.wolkersdorfer@agmt.at
+43 662 6404412
Richard Greil, MD
study chair · AGMT gemeinnützige GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion